UBS keeps USD 15 target for Kura Oncology stock

Published on 10/27/2026 at 18:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kura reported USD 20.87 million revenue in second-quarter 2026. Kura Oncology stock costs EUR 8.71 on October 27, 2026 at 6:53 p.m. CEST.

UBS target and upcoming results

UBS reiterated a USD 15.00 target for Kura Oncology on October 14, 2026.
Kura reported USD 20.87 million revenue for the second quarter of 2026.
Kura Oncology stock costs EUR 8.71 at Lang & Schwarz on October 27, 2026 at 6:53 p.m. CEST.

KURA, US50127T1097, Illustration mit AI erstellt.

Kura Oncology, Inc. (US50127T1097) is trading at EUR 8.71 at Lang & Schwarz on October 27, 2026 at 6:53 p.m. CEST. The latest analyst signal came on October 14, 2026, when Investing.com reported that UBS had reiterated a Buy rating and a USD 15.00 price target. Against the USD 9.71 Nasdaq price at 1:57 p.m. ET, that target stood 54.48 percent above the stock.

Revenue provides a commercial baseline

Kura reported USD 20.87 million revenue for the second quarter of 2026, up from USD 18.27 million in the first quarter. The company also reported a net loss of USD 68.33 million and diluted loss of USD 0.77 per share for the second quarter, compared with a USD 73.33 million net loss and USD 0.83 diluted loss per share in the first quarter.

The figures mark the early commercial phase of Kura's oncology business. Its corporate profile describes KOMZIFTI, or ziftomenib, as an FDA-approved menin inhibitor, while additional programs include darlifarnib and KO-7246, according to Kura Oncology.

Stock range keeps risk visible

KURA was last at USD 9.71 on Nasdaq on October 27, 2026 at 1:57 p.m. ET. The stock's 52-week range was USD 7.36 to USD 13.90, placing the latest Nasdaq price 30.22 percent below the high and 31.93 percent above the low. Market capitalization stood at USD 863.8 million, and trading volume reached 693,335 shares at that timestamp.

November 3 results date approaches

Kura is expected to report third-quarter 2026 results after the market close on November 3, 2026, with a conference call scheduled for 8:00 a.m. ET, according to Transcript Daily. The same report cites analyst expectations for third-quarter revenue of USD 24.86 million and a loss of USD 0.8144 per share. That revenue forecast would be USD 3.99 million above the second-quarter figure.

The November report will test whether revenue can continue rising while losses remain substantial. Kura's second-quarter operating cash flow was negative USD 62.55 million, making commercial execution and cash use central figures for the next update.

Price and upcoming results

Kura combines an analyst target of USD 15.00 with a November 3 reporting date and second-quarter revenue of USD 20.87 million. The further course of trading is shown by the continuously updated real-time quote of Kura Oncology stock.